Engineered Herpes Viruses Show Modest but Meaningful Gains Against Solid Tumors
A meta-analysis of 38 clinical trials finds oncolytic herpes simplex virus therapy delivers modest anti-tumor activity across solid tumors, with ...
A meta-analysis of 38 clinical trials finds oncolytic herpes simplex virus therapy delivers modest anti-tumor activity across solid tumors, with ...
A new Perspective argues that next-generation oncolytic viruses act as antigen-agnostic in situ vaccines capable of priming de novo antitumor ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine